[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100252744":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":51,"collaborators":17,"id":54,"slug":17,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":17,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":17,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":74,"overallStatus":33,"whyStopped":17,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Montana State University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Creatine monohydrate","EXPERIMENTAL","5 grams of daily creatine monohydrate by mouth for 8 weeks",[13],"Drug: Creatine monohydrate",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG",null,[9],[20],"Creapure",[22],{"name":23,"affiliation":5,"role":24},"Tracy Hellem, PhD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":17,"email":29},"CONTACT","406 243 2110","tracy.hellem1@montana.edu",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Montana State University College of Nursing (Missoula campus)","RECRUITING","Missoula","Montana","59812","United States",{"type":39,"coordinates":40},"Point",[41,42],-113.994,46.87215,{"lat":42,"lon":41},[45,48,50],{"name":23,"role":27,"phone":46,"phoneExt":17,"email":47},"406-243-2110","tracy.Hellem1@montana.edu",{"name":17,"role":27,"phone":49,"phoneExt":17,"email":17},"4062432110",{"name":23,"role":24,"phone":17,"phoneExt":17,"email":17},{"type":24,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"Tracy Hellem","Assistant Professor","100252744",false,"NCT02568878","Creatine for Depressed Male and Female Methamphetamine Users","An Open-Label Pilot Study of Creatine for Depressed Male and Female Methamphetamine Users","Inclusion Criteria:\n\n* Current primary diagnosis of methamphetamine dependence or abuse, with methamphetamine preferred drug of abuse\n* Current diagnosis of major depressive disorder (primary or substance-induced)\n* Current diagnosis of an anxiety disorder (primary or substance-induced)\n* Current Hamilton Depression Rating scale score \\> or = to 16\n* Current Hamilton Anxiety Scale score \\> = to 18\n* If taking a psychotropic medication for depressed or anxious mood, regimen must be stable for \\> = to 4 weeks prior to creatine treatment initiation\n\nExclusion Criteria:\n\n* Persons unable to provide adequate informed consent\n* Persons who are at clinically significant suicidal or homicidal risk\n* Primary substance-related diagnosis other than methamphetamine dependence or abuse\n* Positive pregnancy test (females only)\n* History of renal disease\n* Clinically significant medical or neurological illness identified by history, physical exam and laboratory testing\n* History of hypersensitivity reaction to creatine","ALL","18 Years","59 Years",{"count":64,"type":65},29,"ESTIMATED","INTERVENTIONAL",[68],"PHASE3","* Assess the antidepressant\u002Fanxiolytic effect of creatine in male and female methamphetamine users\n* Assess creatine's effect on methamphetamine use\n* Assess the safety of creatine in male methamphetamine users with depression",[71,72,73],"Depression","Anxiety","Methamphetamine Dependence",[71,72,75],"Methamphetamine dependence","2015-12-10",{"date":78,"type":65},"2015-12-11",{"date":80,"type":17},"2015-11",{"date":82,"type":65},"2017-05",{"name":5,"class":6},1]